Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

The gender of cell lines matters when screening for novel anti-cancer drugs.

Nunes LM, Robles-Escajeda E, Santiago-Vazquez Y, Ortega NM, Lema C, Muro A, Almodovar G, Das U, Das S, Dimmock JR, Aguilera RJ, Varela-Ramirez A.

AAPS J. 2014 Jul;16(4):872-4. doi: 10.1208/s12248-014-9617-4. Epub 2014 May 30.

2.

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Kong D, Yamori T.

Bioorg Med Chem. 2012 Mar 15;20(6):1947-51. doi: 10.1016/j.bmc.2012.01.017. Epub 2012 Jan 21. Review.

3.

Development of a high-throughput three-dimensional invasion assay for anti-cancer drug discovery.

Evensen NA, Li J, Yang J, Yu X, Sampson NS, Zucker S, Cao J.

PLoS One. 2013 Dec 11;8(12):e82811. doi: 10.1371/journal.pone.0082811. eCollection 2013.

4.

Large-Scale Drug Screens Support Precision Medicine.

Gray JW, Mills GB.

Cancer Discov. 2015 Nov;5(11):1130-2. doi: 10.1158/2159-8290.CD-15-0945.

5.

High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells.

Hongisto V, Jernström S, Fey V, Mpindi JP, Kleivi Sahlberg K, Kallioniemi O, Perälä M.

PLoS One. 2013 Oct 23;8(10):e77232. doi: 10.1371/journal.pone.0077232. eCollection 2013.

6.

Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents.

Feng R, Rios JA, Onishi T, Lokshin A, Gorelik E, Lentzsch S.

Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.

PMID:
20116850
7.

Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents.

Rao TD, Rosales N, Spriggs DR.

Mol Cancer Ther. 2011 Oct;10(10):1939-48. doi: 10.1158/1535-7163.MCT-11-0228. Epub 2011 Aug 4.

8.

In vitro assays for anticancer drug discovery--a novel approach based on engineered mammalian cell lines.

Gonzalez-Nicolini V, Fussenegger M.

Anticancer Drugs. 2005 Mar;16(3):223-8. Review.

PMID:
15711174
9.

Drug design and testing: profiling of antiproliferative agents for cancer therapy using a cell-based methyl-[3H]-thymidine incorporation assay.

Griffiths M, Sundaram H.

Methods Mol Biol. 2011;731:451-65. doi: 10.1007/978-1-61779-080-5_36.

PMID:
21516428
10.

Translation of a tumor microenvironment mimicking 3D tumor growth co-culture assay platform to high-content screening.

Krausz E, de Hoogt R, Gustin E, Cornelissen F, Grand-Perret T, Janssen L, Vloemans N, Wuyts D, Frans S, Axel A, Peeters PJ, Hall B, Cik M.

J Biomol Screen. 2013 Jan;18(1):54-66. doi: 10.1177/1087057112456874. Epub 2012 Aug 24.

PMID:
22923784
11.

Pathophysiologically relevant in vitro tumor models for drug screening.

Das V, Bruzzese F, Konečný P, Iannelli F, Budillon A, Hajdúch M.

Drug Discov Today. 2015 Jul;20(7):848-55. doi: 10.1016/j.drudis.2015.04.004. Epub 2015 Apr 20. Review.

PMID:
25908576
12.

A high-throughput image-based screen for the identification of Bax/Bak-independent caspase activators against drug-resistant cancer cells.

Seervi M, Sobhan PK, Mathew KA, Joseph J, Pillai PR, Santhoshkumar TR.

Apoptosis. 2014 Jan;19(1):269-84. doi: 10.1007/s10495-013-0921-8.

PMID:
24220853
13.

Precision multidimensional assay for high-throughput microRNA drug discovery.

Haefliger B, Prochazka L, Angelici B, Benenson Y.

Nat Commun. 2016 Feb 16;7:10709. doi: 10.1038/ncomms10709.

14.

High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.

Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, Grafström RC, Perälä M, Kallioniemi O.

Clin Cancer Res. 2009 Oct 1;15(19):6070-8. doi: 10.1158/1078-0432.CCR-09-1035. Epub 2009 Sep 29.

15.

High throughput ratio imaging to profile caspase activity: potential application in multiparameter high content apoptosis analysis and drug screening.

Joseph J, Seervi M, Sobhan PK, Retnabai ST.

PLoS One. 2011;6(5):e20114. doi: 10.1371/journal.pone.0020114. Epub 2011 May 27.

16.

Discovery of small-molecule enhancers of reactive oxygen species that are nontoxic or cause genotype-selective cell death.

Adams DJ, Boskovic ZV, Theriault JR, Wang AJ, Stern AM, Wagner BK, Shamji AF, Schreiber SL.

ACS Chem Biol. 2013 May 17;8(5):923-9. doi: 10.1021/cb300653v. Epub 2013 Mar 25.

17.

Apoptosis assays for quantifying the bioactivity of anticancer drug products.

Brunelle JK, Zhang B.

Drug Resist Updat. 2010 Dec;13(6):172-9. doi: 10.1016/j.drup.2010.09.001. Epub 2010 Oct 13. Review.

PMID:
20947411
18.

Aqueous biphasic cancer cell migration assay enables robust, high-throughput screening of anti-cancer compounds.

Lemmo S, Nasrollahi S, Tavana H.

Biotechnol J. 2014 Mar;9(3):426-34. doi: 10.1002/biot.201300227. Epub 2013 Dec 19.

PMID:
24265131
19.

Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures.

Boehnke K, Iversen PW, Schumacher D, Lallena MJ, Haro R, Amat J, Haybaeck J, Liebs S, Lange M, Schäfer R, Regenbrecht CR, Reinhard C, Velasco JA.

J Biomol Screen. 2016 Oct;21(9):931-41. doi: 10.1177/1087057116650965. Epub 2016 May 27.

20.

Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.

Sandercock AM, Rust S, Guillard S, Sachsenmeier KF, Holoweckyj N, Hay C, Flynn M, Huang Q, Yan K, Herpers B, Price LS, Soden J, Freeth J, Jermutus L, Hollingsworth R, Minter R.

Mol Cancer. 2015 Jul 31;14:147. doi: 10.1186/s12943-015-0415-0.

Supplemental Content

Support Center